{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-25-019062","form_type":"8-K","ticker":"RVPH","cik":"0001742927","company_name":"REVIVA PHARMACEUTICALS HOLDINGS, INC.","filed_at":"2025-06-02T23:59:59+00:00","discovered_at":"2026-05-14T18:02:49.535393+00:00","generated_at":"2026-05-20T03:05:42.745243+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Reviva reports positive full dataset from Phase 3 OLE study of brilaroxazine in schizophrenia","bullets":["Brilaroxazine showed sustained efficacy across all symptom domains: PANSS total score improved -18.1 at 12 months (p≤0.001).","Safety profile well-tolerated: 8.5% TEAEs mostly mild, no drug-related SAEs; discontinuation rate 35%.","Mild weight gain (1.52 kg) and no clinically significant cardiac, liver, or metabolic side effects.","Long-term safety data from 100 patients completing 1 year meets NDA submission requirement for FDA.","Improved multiple neuroinflammatory biomarkers; virtual webcast held June 2, 2025 at 8:00 a.m. EDT."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-25-019062","json":"https://secwatch.observer/filing/0001437749-25-019062.json","markdown":"https://secwatch.observer/filing/0001437749-25-019062.md","text":"https://secwatch.observer/filing/0001437749-25-019062.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1742927/000143774925019062/0001437749-25-019062-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1742927/000143774925019062/rvph20250601_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-20T03:05:42.745243+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}